You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

CLINICAL TRIALS PROFILE FOR GLEOSTINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Gleostine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01989052 ↗ Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated Tactical Therapeutics, Inc. Phase 1 2014-05-01 This is a Phase 1/2 study of the combination of CTO with lomustine in patients with recurrent malignant glioma to be treated at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. The Primary Objectives are: - Phase 1: To determine the maximum tolerated dose (MTD) of CTO when combined with lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) who have not been previously treated with bevacizumab. - Phase 2: To assess the efficacy of CTO (either in monotherapy or in combination with lomustine) compared to lomustine alone in patients with recurrent WHO grade IV malignant gliomas that have not been previously treated with bevacizumab based upon 6-month progression free survival (PFS6). Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and lomustine had been determined for this population. Phase 2 will not proceed.
NCT01989052 ↗ Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma Terminated Annick Desjardins Phase 1 2014-05-01 This is a Phase 1/2 study of the combination of CTO with lomustine in patients with recurrent malignant glioma to be treated at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. The Primary Objectives are: - Phase 1: To determine the maximum tolerated dose (MTD) of CTO when combined with lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) who have not been previously treated with bevacizumab. - Phase 2: To assess the efficacy of CTO (either in monotherapy or in combination with lomustine) compared to lomustine alone in patients with recurrent WHO grade IV malignant gliomas that have not been previously treated with bevacizumab based upon 6-month progression free survival (PFS6). Note: This study was terminated early due to funding issues. At the time of termination, the study was still in Phase 1 and no MTD for the combination of CTO and lomustine had been determined for this population. Phase 2 will not proceed.
NCT02343406 ↗ Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 2 2015-02-17 This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gleostine

Condition Name

Condition Name for Gleostine
Intervention Trials
Glioblastoma 5
Glioblastoma Multiforme 3
Malignant Glioma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gleostine
Intervention Trials
Glioblastoma 9
Glioma 4
Astrocytoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gleostine

Trials by Country

Trials by Country for Gleostine
Location Trials
United States 145
Canada 16
Australia 9
Belgium 9
Germany 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gleostine
Location Trials
California 7
Georgia 6
Washington 6
Texas 6
New York 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gleostine

Clinical Trial Phase

Clinical Trial Phase for Gleostine
Clinical Trial Phase Trials
Phase 3 2
Phase 2/Phase 3 1
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gleostine
Clinical Trial Phase Trials
Recruiting 5
Not yet recruiting 4
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gleostine

Sponsor Name

Sponsor Name for Gleostine
Sponsor Trials
National Cancer Institute (NCI) 3
Kintara Therapeutics, Inc. 1
Children's Oncology Group 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gleostine
Sponsor Trials
Other 11
Industry 10
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.